T1	Premise 900 1056	Gefitinib did not show better OS compared with GP (hazard ratio [HR], 0.932; 95% CI, 0.716 to 1.213; P = .604; median OS, 22.3 v 22.9 months, respectively).
T2	Premise 1057 1157	The 1-year PFS rates were 16.7% with gefitinib and 2.8% with GP (HR, 1.198; 95% CI, 0.944 to 1.520).
T3	Premise 1158 1224	Response rates were 55% with gefitinib and 46% with GP (P = .101).
T4	Premise 1225 1307	Myelosuppression, renal insufficiency, and fatigue were more common in the GP arm,
T5	Premise 1312 1388	skin toxicities and liver dysfunction were more common in the gefitinib arm.
T6	Premise 1389 1475	Two patients (1.3%) in the gefitinib arm developed interstitial lung disease and died.
T7	Claim 1476 1569	Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.
R1	Support Arg1:T6 Arg2:T7	
R2	Support Arg1:T5 Arg2:T7	
R3	Partial-Attack Arg1:T4 Arg2:T7	
R4	Support Arg1:T1 Arg2:T7	
R5	Support Arg1:T2 Arg2:T7	
